Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen’s Stelara receives CHMP backing for psoriatic arthritis

Janssen’s Stelara receives CHMP backing for psoriatic arthritis

30th July 2013

Janssen has announced that its drug Stelara has been recommended for European Commission approval as a treatment for psoriatic arthritis.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has endorsed the product for use alone or in combination with methotrexate among active psoriatic arthritis patients whose response to previous non-biological disease-modifying anti-rheumatic drugs has been inadequate.

Data from two pivotal phase III trials has demonstrated the safety and efficacy of the therapy in this indication, with a final decision from the European regulator expected in the third quarter of 2013.

Dr Jerome Boscia, vice-president and head of immunology development for Janssen's research and development division, said: "We believe Stelara has the potential to play a critically important role in the treatment of this chronic disease and look forward to the European Commission's decision."

This comes after the manufacturer also recently received a CHMP recommendation for approval of Simponi in the treatment of ulcerative colitis.ADNFCR-8000103-ID-801618247-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.